Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer
Eleni Gkika, Elke Firat, Sonja Adebahr, Erika Graf, Ilinca Popp, Gianluca Radicioni, Simon S. Lo, Ursula Nestle, Nils H. Nicolay, Gabriele Niedermann, Dan G. Duda, Anca‐L. Grosu
Abstract
Abstract We performed a prospective study of circulating immune cell changes after stereotactic body radiotherapy (SBRT) in 50 early-stage NSCLC patients. We found no significant increase in CD8 + cytotoxic T lymphocytes at first follow-up (the primary endpoint) but detected a significant increase in expanding Ki-67 + CD8 + and Ki-67 + CD4 + T-cell fractions in patients treated with 10 Gy or less per fraction. SBRT can induce significant expansion in circulating effector T-cells immediately post-treatment.
Topics & Concepts
CD8MedicineImmune systemLung cancerClinical endpointCytotoxic T cellRadiosurgeryStage (stratigraphy)Radiation therapyOncologyLungEffectorInternal medicineImmune modulationProspective cohort studyT cellGastroenterologyImmunologyClinical trialBiologyIn vitroPaleontologyBiochemistryCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentInflammatory Biomarkers in Disease Prognosis